ProfoundBio is a clinical-stage biotechnology company focused on developing antibody–drug conjugates (ADCs) for the treatment of cancer. The company integrates monoclonal antibodies with cytotoxic payloads using advanced linker-payload chemistries designed to improve stability in circulation and enable tumor-selective drug release, aiming to enhance efficacy and reduce off-target toxicity.
Its pipeline includes rinatabart sesutecan (Rina-S), an ADC targeting folate receptor alpha (FRα) in ovarian and other FRα-expressing solid tumors, alongside additional ADC candidates directed at clinically relevant tumor antigens. ProfoundBio’s capabilities span discovery, preclinical development, and early clinical translation of next‑generation ADCs, with an emphasis on site-specific conjugation and optimized payload/linker design. In 2024, ProfoundBio became part of Genmab, supporting the expansion of a broader oncology-focused ADC portfolio.
None yet. When a new project in the record names ProfoundBio as owner, partner or investor, it shows here.
Genmab shifts focus to high-impact projects in its late-stage pipeline, ensuring no change to 2025 financial guidance.
